CDMO

Recent developments

Capacity and footprint

WuXi Biologics advanced build‑out with the topping‑out of a modular drug‑product facility at the Singapore CRDMO Hub and structural completion of the Chengdu microbial commercial manufacturing site. Evonik committed US$100 million to upgrade the Tippecanoe Labs site in Lafayette, Indiana and expanded biotech drug‑substance capacity at the Fermas site in Slovenská Ľupča.

Regulatory clearances

Network readiness improved as the MFG8 drug substance facility in Hebei cleared FDA PLI; ANVISA GMP certification was earned for MFG2, DP1 and DPPC; and MFDS GMP certification covered MFG5, DP2 and DPPC. The Suzhou Biosafety Testing Center secured a fourth EMA GMP certificate, and AGC Biologics’ Seattle site received Anvisa GMP.

Integrated services, deals

AGC Biologics partnered with Pyramid Pharma Services to add U.S. sterile fill‑finish. It will also develop and manufacture KTP‑001 for Teikoku Pharma and started GMP work on NN4101 with Novelty Nobility.

WuXi Biologics signed a license agreement with Vertex for a trispecific T‑cell engager and partnered with Sinorda Biomedicine on SND006 for autoimmune indications.

Process and platform advances

Evonik and evitria launched the eviCHO transient expression kit, and WACKER introduced Contract Research Services for nucleic‑acid modalities and LNPs.

Asahi Kasei installed an FO–MD system at Peptistar; Toray introduced a high‑efficiency separation membrane module; and Aptar reported preclinical proof‑of‑concept for intranasal and pulmonary GLP‑1 delivery.

Financing and restructuring

The EIB financed Orano Med’s Advanced Thorium Extraction Facility and, with EC and IFC, backed Biovac’s end‑to‑end multi‑vaccine manufacturing facility in South Africa. Evonik sold Hanau pharmaceutical‑ingredient assets to ProChem, and CELLforCURE sought a buyer for its Les Ulis site amid weaker funding for cell and gene therapy.